Replimune Group (NASDAQ:REPL) Stock: Insider Kapil Dhingra Sells 21,500 Shares

Replimune Group, Inc. (NASDAQ:REPL) Director Kapil Dhingra sold 21,500 shares of the company’s stock in a transaction that occurred on Monday, November 2nd. The stock was sold at an average price of $19.00, for a total transaction of $408,500.00. Following the completion of the transaction, the director owned 21,669 shares in the company, valued at approximately $411,711. This represents a 49.80% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Replimune Group Stock Performance

NASDAQ:REPL opened at $20.69 on Thursday. The company has a debt-to-equity ratio of 0.59, a quick ratio of 6.90 and a current ratio of 7.11. The stock has a market capitalization of $1.96 billion, a P/E ratio of -7.42 and a beta of 0.93. The company has a 50 day moving average price of $13.89 and a 200 day moving average price of $9.53. Replimune Group, Inc. has a fifty-two week low of $1.50 and a fifty-two week high of $21.26.

Replimune Group (NASDAQ:REPL) last announced its earnings results on Wednesday, October 28th. The company reported ($0.54) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.78) by $0.24. Equities research analysts forecast that Replimune Group, Inc. will post -2.40 EPS for the current year.

Institutional Trading of Replimune Group

Large investors have recently modified their holdings of the stock. BlackRock Inc. purchased a new position in Replimune Group in the second quarter valued at $99,171,000. Montanova Capital LLC grew its stake in Replimune Group by 4.0% during the 2nd quarter. Montanova Capital LLC now owns 4,389,836 shares of the company’s stock worth $48,595,000 after purchasing an additional 168,000 shares in the last quarter. Opaleye Management Inc. acquired a new position in Replimune Group during the 2nd quarter worth $15,332,000. Dimensional Fund Advisors LP increased its holdings in Replimune Group by 1.9% during the 1st quarter. Dimensional Fund Advisors LP now owns 1,140,099 shares of the company’s stock worth $8,719,000 after purchasing an additional 20,742 shares during the period. Finally, EcoR1 Capital LLC purchased a new stake in Replimune Group during the 1st quarter worth about $7,650,000. Hedge funds and other institutional investors own 92.53% of the company’s stock.

Wall Street Analysts Forecast Growth

REPL has been the topic of several research reports. Piper Sandler raised Replimune Group from a “hold” rating to a “strong-buy” rating in a research note on Friday, July 31st. JPMorgan Chase & Co. boosted their price target on shares of Replimune Group from $20.00 to $21.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 26th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Replimune Group in a research note on Monday, October 5th. Leerink Partners increased their price target on shares of Replimune Group from $19.00 to $31.00 and gave the stock an “outperform” rating in a research report on Thursday, October 29th. Finally, Wedbush raised shares of Replimune Group from a “neutral” rating to an “outperform” rating and set a $12.00 price objective for the company in a research note on Friday, August 7th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $14.33.

About Replimune Group

Replimune Group, Inc is a clinical-stage biotechnology company developing cancer immunotherapies designed to stimulate the immune system to recognize and attack tumors. The company’s approach focuses on oncolytic immunotherapy, using genetically engineered viruses intended to selectively infect and destroy tumor cells while also activating broader antitumor immune responses.

Replimune’s lead product candidate is RP1, also known as vusolimogene oderparepvec, an engineered oncolytic herpes simplex virus type 1 designed to replicate within tumors and promote systemic immune activity.